Published in Br J Haematol on April 01, 2006
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med (2003) 3.32
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 2.50
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology (2014) 2.12
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 2.04
Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol (2006) 1.95
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med (2007) 1.63
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med (2016) 1.60
The prognosis for individuals on disability retirement. An 18-year mortality follow-up study of 6887 men and women sampled from the general population. BMC Public Health (2006) 1.54
Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost (2010) 1.47
[Diagnosis of acute pulmonary embolism. Simplified strategy based on clinical probability, D-dimer and computer tomography]. Lakartidningen (2006) 1.40
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. Thromb Haemost (2012) 1.37
Cervical artery dissection: pathology, epidemiology and management. Thromb Res (2009) 1.33
Sick-leave track record and other potential predictors of a disability pension. A population based study of 8,218 men and women followed for 16 years. BMC Public Health (2009) 1.23
Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a population-based study of 23 796 consecutive autopsies. Eur Heart J (2005) 1.19
Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke (2010) 1.19
The prevalence of oral ulceration in Swedish horses when ridden with bit and bridle and when unridden. Vet J (2008) 1.13
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.11
Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost (2006) 1.09
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res (2011) 1.03
Effects of self-rated health on sick leave, disability pension, hospital admissions and mortality. A population-based longitudinal study of nearly 15,000 observations among Swedish women and men. BMC Public Health (2012) 1.01
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail (2005) 0.99
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96
Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public Health (2008) 0.95
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost (2008) 0.93
Streptococcus devriesei sp. nov., from equine teeth. Syst Appl Microbiol (2004) 0.93
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res (2002) 0.93
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol (2013) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost (2003) 0.89
Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem (2003) 0.89
Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol (2009) 0.87
Thrombosis is associated with inferior survival in multiple myeloma. Haematologica (2012) 0.86
Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol (2013) 0.84
A population-based study of nearly 15 000 observations among Swedish women and men during 1973-2003. BMJ Open (2012) 0.83
The influence of productivity and width of littoral zone on the trophic position of a large-bodied omnivore. Oecologia (2008) 0.83
Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost (2012) 0.81
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost (2012) 0.81
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis (2007) 0.81
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost (2010) 0.81
Effects of stream predator richness on the prey community and ecosystem attributes. Oecologia (2008) 0.81
Acquired hemophilia masked by warfarin therapy: report on two cases. Blood Coagul Fibrinolysis (2003) 0.80
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. J Thromb Thrombolysis (2014) 0.80
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost (2016) 0.80
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost (2015) 0.80
Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis (2003) 0.80
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. Semin Hematol (2011) 0.80
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis (2015) 0.80
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model. Thromb Haemost (2006) 0.80
Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. Thromb Res (2012) 0.79
Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clin Pharmacokinet (2006) 0.79
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. Thromb Haemost (2013) 0.79
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost (2010) 0.79
Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. Curr Med Res Opin (2006) 0.78
[Diagnosis of pulmonary embolism in pregnant women. Scintigraphy or computer tomography?]. Lakartidningen (2010) 0.78
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost (2013) 0.78
Bioequivalence of ximelagatran, an oral direct thrombin inhibitor, as whole or crushed tablets or dissolved formulation. Curr Med Res Opin (2004) 0.77
Optimal reversal of vitamin K antagonists. Thromb Res (2005) 0.77
Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy (2013) 0.77
Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis? Blood Coagul Fibrinolysis (2012) 0.77
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. Thromb Haemost (2005) 0.77
Bile acids and coagulation factors: paradoxical association in children with chronic liver disease. Eur J Gastroenterol Hepatol (2013) 0.77
Heavy metals and stable isotopes in a benthic omnivore in a trophic gradient of lakes. Environ Sci Technol (2007) 0.76
Overweight and hypertriglyceridemia are risk factors for liver cirrhosis in middle-aged Swedish men. Scand J Gastroenterol (2011) 0.76
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V. Haematologica (2008) 0.76
NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study. J Clin Pharmacol (2007) 0.76
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos (2006) 0.76
Recombinant FVIIa in children with liver disease. Thromb Res (2005) 0.76
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin Thromb Hemost (2009) 0.76
Extended anticoagulation in venous thromboembolism. N Engl J Med (2013) 0.76